The second wave in kinase cancer drugs

  title={The second wave in kinase cancer drugs},
  author={Ken Garber},
  journal={Nature Biotechnology},
When the US Food and Drug Association (FDA) gave its blessing in December to Nexavar (sorafenib), from Onyx Pharmaceuticals in Emeryville, California, it marked the fifth drug approval of a protein kinase inhibitor in the last four years for treating cancer. And the pace is quickening. Two more companies are awaiting almost certain FDA approval for their kinase inhibitors (Table 1) and at least 40 are in clinical trials, making kinases the second most popular drug target class in the… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Explore Further: Topics Discussed in This Paper


Publications citing this paper.
Showing 1-10 of 28 extracted citations

Targeting the NF-κB pathway in cancer therapy.

Surgical oncology clinics of North America • 2013
View 1 Excerpt


Publications referenced by this paper.

NEWS FEATURE © 20 06 N at ur e P ub lis hi ng G ro up ht tp :// w w w .n at ur e. co m

K Podsypanina
Proc Natl Acad Sci USA, • 2001

Similar Papers

Loading similar papers…